Schulman IRB announced its commercial institutional biosafety committee (IBC) service is now open.
The commercial IBC service provides comprehensive support for research sponsors and sites conducting research involving recombinant DNA (genetic engineering), offering research sponsors, CROs and institutions an independent option for establishing IBCs when required by federal guidelines.
Led by Dr. Daniel Eisenman, Ph.D., RBP, SM (NRCM), CBSP, Schulman's IBC service supports clinical, pre-clinical and non-clinical research, providing all components to complement an existing IBC or build and administer an entirely new IBC.
"We are thrilled to now offer IBC services as a part of Schulman's extensive suite of research compliance services," Michael Woods, President and CEO of Schulman IRB said. "By coordinating IBC review with the IRB review, we will provide clients with the expertise and efficiencies necessary to conduct genetic engineering research safely and with minimal regulatory delay."
NIH Guidelines require both IRB and IBC review for gene therapy (human gene transfer) research funded by NIH or taking place at sites that receive NIH funding. The IBC reviews safety aspects of research involving recombinant DNA, including risks associated with genetic modifications and experimental procedures as well as occupational and environmental safety.